Phase 2 rebuild — mitochondrial biogenesis and metabolic flexibility (Weeks 5-10)

Now you're not just fueling — you're making new mitochondria.

Phase 1 stabilized what you already had. You gave the electron transport chain a cleaner runway, you replenished the NAD+ pool that aging had let drain, you let cellular respiration catch its breath. None of that builds new infrastructure. By Week 5, the existing mitochondrial population is healthier — but it's still the same population. Phase 2 is when you flip from maintenance to construction. MOTS-c, the mitochondrial-encoded signaling peptide that the corpus describes as "the factory that builds the factory," moves to the front of the stack. You stop fueling old mitochondria and start building new ones.

What's actually happening at the cellular level

MOTS-c is encoded in mitochondrial DNA itself — a peptide produced by the organelles it then optimizes. Its mechanism is AMPK activation, often called the "metabolic master switch." AMPK is the sensor that tells the cell to burn fat, increase glucose uptake, shift toward fatty acid oxidation, and — critically for Phase 2 — trigger mitochondrial biogenesis. The corpus is explicit: MOTS-c "doesn't just boost existing mitochondria; it builds the machinery inside them." Practitioner consensus treats this as an exercise-mimetic pathway, activating the same metabolic cascades as vigorous training without the mechanical load.

The second lever is NNMT inhibition. 5-Amino-1MQ blocks nicotinamide N-methyltransferase, the enzyme that quietly drains the NAD+ salvage pathway by methylating away nicotinamide before it can be recycled. In adipose tissue, NNMT is overexpressed in metabolic dysfunction — it's a major reason NAD+ pools collapse with age and obesity. Inhibiting it does two things at once: it preserves NAD+ availability (compounding what Phase 1 started) and it promotes lipolysis directly. The substrate frames it as "NAD+ amplifier plus fat burner," and the dosing reflects that dual mechanism — oral, daily, 100-150mg.

Where this stack diverges from a generic biogenesis protocol is the membrane-level work. Mitochondrial biogenesis without cardiolipin integrity is just building broken factories faster. Cardiolipin is the lipid that anchors the electron transport chain to the inner mitochondrial membrane; when it oxidizes (and it oxidizes preferentially under inflammation), the ETC leaks electrons, generates reactive oxygen species, and degrades the very organelles you're trying to build. SS-31 (Elamipretide) concentrates 1000x at cardiolipin and stabilizes it. The corpus tier-rates this Clinical based on the PROGRESS-HF trial work and primary mitochondrial myopathy studies. Most NAD+ paths skip it. This one doesn't.

The Phase 2 stack (Weeks 5-10)

Cycle architecture: MOTS-c runs 4-8 weeks on, then a 4-week rest period. In a 10-week path, that maps to Weeks 5-10 on, then a planned washout in the maintenance phase (covered in Module 10). 5-Amino-1MQ can run continuously through the washout — they're complementary, not redundant.

Stacking with Phase 1: Don't drop the Phase 1 stabilizers when you add Phase 2. Methylene Blue stays. The Phase 1 low-dose NMN steps up. You're layering, not swapping.

What you should feel, week by week

• Week 5-6: Energy floor lifts. Mid-afternoon crash softens or disappears. Cognitive clarity improves first — the brain is the most mitochondria-dense organ and feels biogenesis fastest. Some users report a transient warming sensation post-MOTS-c injection. This is AMPK-mediated thermogenesis. It's expected.
• Week 6-7: Training capacity changes. Time to fatigue extends. Recovery between sets shortens. Fat oxidation during fasted morning training is noticeably easier. The corpus describes this as "metabolic flexibility returning."
• Week 7-8: Body composition shifts. Visceral and subcutaneous fat — particularly stubborn abdominal fat that resisted Phase 1 — begins to mobilize. This is the 5-Amino-1MQ NNMT lever doing its work. Waist measurements move before scale weight does.
• Week 8-10: Sustained appetite regulation, improved fasting insulin (if you're tracking), better sleep architecture, and what practitioner consensus describes as "youthful baseline energy" — energy that's present without stimulants and doesn't crash.

What's NOT happening yet

• You're not reversing telomere length. That's Epitalon territory, and it operates at the genetic level on a different timeline. Mitochondrial biogenesis is downstream of cellular replication capacity, not a substitute for it.
• You're not getting full hormonal axis restoration. GH-axis recovery (covered in Module 5) is a separate intervention. If your IGF-1 was low in baseline labs, MOTS-c will not move it meaningfully.
• You're not eliminating senescent cells. Mitochondrial peptides optimize live cells. Zombie-cell clearance is a separate protocol layer.
• You're not bypassing the substrate. If inflammation is still driving an oxidative burst at the mitochondrial level (high CRP, persistent IL-6 elevation), the new mitochondria you're building will degrade as fast as you build them. The Three Root Causes Framework is explicit: inflammation gets addressed before — or alongside — mitochondrial work, never ignored.
• You're not feeling "more energy" the way a stimulant works. This is not adrenergic. The shift is structural. If you're expecting a caffeine-like lift, you'll undersell what's actually changing.

Markers worth tracking through Week 10

Lactate/pyruvate ratio (elevated = mitochondrial dysfunction; the trend should bend down). NAD+/NADH ratio if you have access. Fasting insulin and HOMA-IR. Resting heart rate (biogenesis tends to lower it). Subjective energy at 3pm — the most honest field measurement you have.

The practitioner corpus describes this stack. Track the markers. Adjust the doses to what your body is actually telling you.